Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 18/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 17/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965002 | 0.95 | ESR1 (0.50) | ESR1ESR2MGAMGAASI | |
| SCHEMBL4965999 | 0.85 | ESR1 (0.53) | ESR1ESR2 | |
| SCHEMBL4966004 | 0.83 | MAPT (0.40) | ESR1ESR2HDAC1HDAC2MGAM | |
| SCHEMBL4965974 | 0.81 | ESR1 (0.49) | ESR1ESR2GAA | |
| SCHEMBL4965276 | 0.78 | HDAC1 (0.36) | ESR1ESR2HDAC1HDAC2MGAM | |
| SCHEMBL10597263 | 0.73 | ESR1 (0.37) | ESR1ESR2 | |
| SCHEMBL7589490 | 0.72 | ESR1 (0.47) | ESR1ESR2 | |
| SCHEMBL5851908 | 0.72 | ESR1 (0.54) | ESR1ESR2 | |
| SCHEMBL4966676 | 0.72 | HDAC1 (0.36) | ESR1ESR2HDAC1HDAC2 | |
| SCHEMBL10597919 | 0.72 | CDK4 (0.36) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641774-B1 | PENTAFLUOROALKANESULFINYL NAPHTHALENES AND RELATED ESTROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-09-03 | — | — | EP | claimed |
| US-20070054956-A1 | Pentalfluoroalkanesulfinyl naphthalenes and related estrogen receptor modulators | ELI LILLY AND COMPANY | 2007-03-08 | — | — | US | claimed |
| EP-1641774-A1 | PENTAFLUOROALKANESULFINYL NAPHTHALENES AND RELATED ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-04-05 | — | — | EP | claimed |
| WO-2005000834-A1 | PENTAFLUOROALKANESULFINYL NAPHTHALENES AND RELATED ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | claimed |
| US-7462647-B2 | Pentalfluoroalkanesulfinyl naphthalenes and related estrogen receptor modulators | ELI LILLY AND COMPANY (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1641774-B1 | PENTAFLUOROALKANESULFINYL NAPHTHALENES AND RELATED ESTROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20070054956-A1 | Pentalfluoroalkanesulfinyl naphthalenes and related estrogen receptor modulators | ELI LILLY AND COMPANY | 2007-03-08 | — | — | US | disclosed |
| EP-1641774-A1 | PENTAFLUOROALKANESULFINYL NAPHTHALENES AND RELATED ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005000834-A1 | PENTAFLUOROALKANESULFINYL NAPHTHALENES AND RELATED ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054956-A1 | Pentalfluoroalkanesulfinyl naphthalenes and related estrogen receptor modulators | ESR2, ESR1, GPER1 | ESR1 2/4885ESR2 1/4885HDAC1 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.